---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Diagnosis"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Diagnosis. Topics: Diagnostic testing; Systematic literature review of HAE disease burden: diagnostic delay; Guideline recommendation: initial C1-INH functional assay; Laboratory findings: C4, C1-INH antigen, and C1-INH function; 4 further topics. 8 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/diagnosis"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Diagnostic testing

> “Measurements of serum/plasma levels of C1–INH function, C1–INH protein, and C4 are used to diagnose HAE-1/2”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.1.5-2"></a>

### Systematic literature review of HAE disease burden: diagnostic delay

> “The mean or median delay from the first onset of a symptom of HAE to confirmed diagnosis ranged from 3.9 to 26 years.”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="topic-2.2.1.5-3"></a>

### Guideline recommendation: initial C1-INH functional assay

> “We recommend that all patients for whom HAE is suspected undergo an initial assessment with a C1-INH functional assay, as long as it is performed by a specialized laboratory using an accurate, validated method.”
> “If the C1-INH functional assay is unavailable or unreliable, the diagnosis can still be confirmed through quantitative C1-INH measurement and/or genetic testing for SERPING1.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-4"></a>

### Laboratory findings: C4, C1-INH antigen, and C1-INH function

> “C4 levels are low in 90%–95% of patients with HAE-C1-INH during asymptomatic periods and are almost always low during acute attacks.”
> “In HAE type 1, C1-INH antigen levels are reduced, whereas in HAE type 2, they are normal or elevated.”
> “In HAE-C1-INH, functional activity is typically less than 50% of normal levels.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-5"></a>

### Guideline recommendations: genetic testing and cascade family testing

> “We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.”
> “We recommend cascade family testing for HAE when an index case is diagnosed, either through C1-INH testing or genetic testing, as appropriate based on age and diagnosis (HAE-C1-INH vs. HAE-nC1-INH).”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-6"></a>

### Diagnostic delay over time

> “Fortunately, diagnostic delay in HAE has declined considerably in the last decades, from an average of 21 years in the 1970s to around 7–10 years currently”
> “Under 40% of patients receive a diagnosis within 1 to 3 years after symptom onset.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-7"></a>

### Diagnostic delay: US patient registry

> “Delay to diagnosis was shorter in HAE-C1INH (5 vs 11 years), but both had decreasing delays over time.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.5-8"></a>

### Age at diagnosis and diagnoses preceding HAE: Finnish national register

> “Mean age at the time of diagnosis was 39 years, with 22.5% diagnosed at ≤18 years, and 13.6% before or at the age of 12.”
> “Of note, 37% had a diagnosis of angioedema before the first HAE diagnosis, 17% a diagnosis of oedema, whereas 6% had been diagnosed with urticaria, suggesting misdiagnosed HAE or unrelated urticaria.”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
